Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy.
Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy.
复制标题
乳腺癌患者放疗后 18F-FDG 摄取代谢特征的预后价值
DOI：
10.1016/j.omto.2021.10.008
复制
发表时间：
2021-12-17
期刊：
影响因子：
--
通讯作者：
Guo X
中科院分区：
文献类型：
--
作者：
Meng J;Deshayes E;Zhang L;Shi W;Zhang X;Chen X;Mei X;Ma J;Jiang Y;Wu J;Shao Z;Yu X;Yang Z;Guo X
Radiotherapy (RT) is a major modality of postoperative treatment in breast cancer. The maximal standardized value (SUVmax) is 18FDG-PET/CT derived parameter that reported to be a valuable prognostic factor in cancer patients. Herein, we aimed to identify a prognostic gene signature associated with glucose uptake for breast cancer patients after RT by leveraging the mRNA expression profiling on public datasets. The glucose uptake signature was constructed using the single sample gene set enrichment analysis (ssGSEA) algorithm and evaluated in GSE21217 where SUVmax value was measured by PET-CT directly. The prognostic value was validated in three post-RT breast cancer cohorts (GSE103744, NKI, and FUSCC databases). The patients were stratified into glucose uptake signature score-high and low groups. Patients with a higher score had worse survival than those with a lower score. Mechanistically, the glucose uptake signature was calculated in each cell type of a single-cell RNA-seq database from five breast cancer patients. Glucose uptake signature score was significantly elevated in the malignant epithelial cells compared with normal ones. The immunosuppression markers including PDCD1, TIGIT, LAG3, and HAVCR2 were significantly upregulated in the T cells bearing a high glucose uptake signature score. Collectively, our results demonstrated the potential prognostic value of a glucose uptake signature in the post-RT breast cancer patients. A glucose uptake gene signature was constructed and validated to predict survival in radiotherapy-treated breast cancer patients. The correlation between this gene signature and immunosuppressive markers has been explored.
登录
查看更多内容
影响因子：
29
作者：
Cascone T;McKenzie JA;Mbofung RM;Punt S;Wang Z;Xu C;Williams LJ;Wang Z;Bristow CA;Carugo A;Peoples MD;Li L;Karpinets T;Huang L;Malu S;Creasy C;Leahey SE;Chen J;Chen Y;Pelicano H;Bernatchez C;Gopal YNV;Heffernan TP;Hu J;Wang J;Amaria RN;Garraway LA;Huang P;Yang P;Wistuba II;Woodman SE;Roszik J;Davis RE;Davies MA;Heymach JV;Hwu P;Peng W
通讯作者：
Peng W
影响因子：
11.5
作者：
Meijer, Tineke W. H.;Kaanders, Johannes H. A. M.;Bussink, Johan
通讯作者：
Bussink, Johan
三阴性乳腺癌的基因组和转录组景观：亚型和治疗策略
影响因子：
50.3
作者：
Jiang, Yi-Zhou;Ma, Ding;Shao, Zhi-Ming
通讯作者：
Shao, Zhi-Ming
影响因子：
64.5
作者：
Ho PC;Bihuniak JD;Macintyre AN;Staron M;Liu X;Amezquita R;Tsui YC;Cui G;Micevic G;Perales JC;Kleinstein SH;Abel ED;Insogna KL;Feske S;Locasale JW;Bosenberg MW;Rathmell JC;Kaech SM
通讯作者：
Kaech SM
影响因子：
11.2
作者：
Palaskas N;Larson SM;Schultz N;Komisopoulou E;Wong J;Rohle D;Campos C;Yannuzzi N;Osborne JR;Linkov I;Kastenhuber ER;Taschereau R;Plaisier SB;Tran C;Heguy A;Wu H;Sander C;Phelps ME;Brennan C;Port E;Huse JT;Graeber TG;Mellinghoff IK
通讯作者：
Mellinghoff IK